Ischemic stroke occurs when a blood vessel supplying the brain is obstructed.
Consider stroke in any patient presenting with sudden focal neurological deficit or any alteration in level of consciousness.
Rapid evaluation is essential for sure of time-sensitive treatments.
Determine if patient's symptoms are due to stroke and exclude stroke mimics (eg migraine, hypertensive encephalopathy, hypoglycemia, seizures or post-ictal paresis); identify other conditions requiring immediate intervention and determine the potential causes of stroke.
Patients with COVID-19 who experience an ischaemic stroke may have worse outcomes, including greater stroke severity and mortality risk, than those without COVID-19, findings from the Global COVID-19 Stroke Registry showed.
In stroke rehabilitation, performing aerobic and stepping exercises at a higher intensity and frequency within a critical time period can boost the recovery and improve the quality of life of patients, according to the results of a phase II trial.
Use of a 7-day Holter monitoring for poststroke atrial fibrillation (AF) screening in a primary care setting appears to increase the number of AF cases, markedly improving the detection rate compared with pulse palpation and 12-lead electrocardiogram (ECG), according to a study.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
A novel, noninvasive wearable brain stimulation device that delivers continuous transcranial magnetic stimulation to induce the brain to rewire itself significantly increases brain activity and is safe in patients with chronic ischaemic stroke — thus presenting a step forward to improving motor function after stroke, suggests a preliminary study presented at ISC 2020 Meeting.
A multicenter trial to investigate whether antithrombotic therapy can be initiated in atrial fibrillation (AF) patients who have survived an intracerebral haemorrhage (ICH) can be done, based on the results of the phase II feasibility trial NASPAF-ICH* presented at the 2020 International Stroke Conference (ISC).
Being male and having a high genetic predisposition to sustain an acute vascular event (AVE) predict greater risks of stroke and myocardial infarction (MI) than either factor does alone in a population of middle-aged individuals without vascular risk factors, as shown in a study presented at the International Stroke Conference (ISC) 2020.
Patients with atherosclerotic disease who have had an ischaemic stroke or transient ischaemic attack (TIA) may fare better with a lower low-density lipoprotein cholesterol (LDL-C) target, as reducing LDL-C levels even below the 90–110 mg/dL target range at <70 mg/dL confers superior protection against the risk of subsequent stroke, according to data from the Treat Stroke to Target trial.